Treatment of Psychotic Major Depression With Mifepristone
Researchers are comparing Mifepristone (RU-486) and placebo to find out how the approaches affect psychotic symptoms in people with depression.
Understand this study
What is this study about?
Researchers are comparing Mifepristone (RU-486) and placebo to find out how the approaches affect psychotic symptoms in people with depression.
Who could participate?
Listed age limits: 21 years to 85 years.
- Listed locations
- StanfordSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 10
- Sponsor
- Stanford University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 21 Years to 85 Years
- Official registry ID
- NCT00867360
- Official title
Show the full official title
Hypothalamic-Pituitary-Adrenal (HPA)/Dopamine Axis in Psychotic Depression
Recruitment & locations
Stanford
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are comparing Mifepristone (RU-486) and placebo to find out how the approaches affect psychotic symptoms in people with depression.
Who is behind this study?
The study sponsor is Stanford University, a university.
Does this study involve medication?
Yes. The study involves medication, including Mifepristone (RU-486) and Placebo.
Who can participate?
Listed age limits: 21 years to 85 years.
Is this study still recruiting?
The registry lists this study as terminated.
